Angiochem Funding: How Much Did They Raise & Key Investors

How Much Did Angiochem Raise?
Funding & Key Investors

Angiochem, a clinical-stage biotechnology firm focused on neurological diseases, has secured $7.5M in total capital, with its most recent financing round bringing in $7.5M through a major strategic investment. This significant backing underscores the company's progress in developing novel peptide drug conjugates.

What is Angiochem?

Angiochem

Business Services

Research & Development

Angiochem is a biotechnology company established in 2003 and headquartered in Quebec, Canada. The company is dedicated to the discovery and development of innovative peptide drug conjugates aimed at treating neurological disorders. Its clinical-stage focus suggests a pipeline of potential therapies moving through rigorous testing phases.

How much funding has Angiochem raised?

Angiochem has raised a total of $7.5M across 1 funding round:

2018

Series C

$7.5M

Series C (2018): $7.5M, investors not publicly disclosed

What's next for Angiochem?

The recent major strategic investment indicates a pivotal moment for Angiochem, likely enabling the acceleration of its drug development pipeline and clinical trials. This infusion of capital is expected to support the company's efforts to advance its therapeutic candidates towards regulatory approval and potential market entry, solidifying its position in the competitive landscape of neurological disease treatment.

See full Angiochem company page

See More Financial Insights